The mechanisms of NO inhibition of CaMK [Ca 2+ /CaM (calmodulin)-dependent protein kinase] II activity were studied. In rat pituitary tumour GH3 cells, TRH [thyrotrophin (TSH)-releasing hormone]-stimulated phosphorylation of nNOS [neuronal NOS (NO synthase)] at Ser 847 was sensitive to an inhibitor of CaMKs, KN-93, and was enhanced by inhibition of nNOS with 7NI (7-nitroindazole). Enzyme activity of CaMKII following in situ treatment with 7NI was also increased. The in vitro activity of CaMKII was inhibited by co-incubation either with nNOS and L-arginine or with NO donors SNAP (S-nitroso-N-acetyl-DL-penicillamine) and DEA-NONOate [diethylamine-NONOate (diazeniumdiolate)]. Once inhibited by these treatments, CaMKII was observed to undergo full reactivation on the addition of a reducing reagent, DTT (dithiothreitol). In transfected cells expressing CaMKII and nNOS, treatment with the calcium ionophore A23187 further revealed nNOS phosphorylation at Ser 847 , which was enhanced by 7NI and CaMKII S-nitrosylation. Mutated CaMKII (C6A), in which Cys 6 was substituted with an alanine residue, was refractory to 7NI-induced enhancement of nNOS phosphorylation or to CaMKII S-nitrosylation. Furthermore, we could identify Cys 6 as a direct target for S-nitrosylation of CaMKII using MS. In addition, treatment with glutamate caused an increase in CaMKII S-nitrosylation in rat hippocampal slices. This glutamate-induced S-nitrosylation was blocked by 7NI. These results suggest that inactivation of CaMKII mediated by S-nitrosylation at Cys 6 may contribute to NO-induced neurotoxicity in the brain.
INTRODUCTION
CaMK [Ca 2+ /CaM (calmodulin)-dependent protein kinase] II is a holoenzyme composed of ∼ 12 monomers, which are primarily α-and β-subunits in neurons, and is a major component of PSDs (postsynaptic densities) [1] . It phosphorylates several key postsynaptic targets, including the N-methyl-D-aspartate receptor subunit NR2B (N-methyl-D-aspartate receptor subunit 2B) [2] , the AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor subunit GluR1 (glutamate receptor 1) [3] and the insect Discs large [4] . The Ras-GAP (GTPase-activating protein) SynGAP, localized to the PSD through its interaction with the scaffold protein PSD-95, is phosphorylated and inhibited by CaMKII [5] , and another CaMKII substrate anchored to PSD-95 is nNOS [neuronal NOS (NO synthase)] [6] .
NO, generated by NOS, is a signalling molecule that regulates many biological processes in the nervous system, including neurotransmitter release, plasticity and apoptosis [7] [8] [9] . Protein S-nitrosylation, the interaction of reactive nitrogen oxides with cysteine sulfhydryls, has emerged as a prototype of guanylate cyclase-independent, redox-dependent post-translational modification leading to altered protein function [10] , as demonstrated for the N-methyl-D-aspartate receptor [8] , the ryanodine receptor [11] , caspase 3 [12] and G-protein-coupled receptor kinase 2 [13] . Endogenous S-nitrosylation of parkin [14] , matrix-metalloproteinase 9 [15] , N-ethylmaleimide sensitive factor [16] , protein disulfide-isomerase [17] and serine racemase [18] is strongly linked with nNOS activity. In contrast to phosphorylation, nitrosylation is an enzyme-independent process. However, both modifications are reversible and specific, allowing cells to flexibly and precisely modify protein function in response to environmental signals [19] . In the nervous system, nNOS appears to be targeted to membranes by binding to PSD-95 that associates with N-methyl-D-aspartate receptors at synapses [20] . Snitrosylation of several neuronal proteins in brain, including some known to co-localize with nNOS, is abrogated in the brain of nNOS −/− mice [21] . It has been established that nNOS is directly phosphorylated by CaMKII [6, 22] and co-localization of CaMKII, nNOS, and PSD-95 is important in this regard [23] . In this present paper, we investigated the role of NO in the regulation of CaMKII in the nNOS expressing cells and demonstrated S-nitrosylationmediated inactivation of CaMKII.
MATERIALS AND METHODS

Materials
The cDNA for rat brain nNOS was a gift from Dr Solomon H. Snyder (Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.) [24] . Recombinant Abbreviations used: ACSF, artificial cerebrospinal fluid; CaM, calmodulin; CaMK, Ca 2+ /CaM-dependent protein kinase; DEA-NONOate, diethylamineNONOate (diazeniumdiolate); DTT, dithiothreitol; ESI, electrospray ionization; GAP, GTPase-activating protein; HEK-293 cell, human embryonic kidney cell; HEN, Hepes, EDTA and neocuprione; KRH, Krebs-Ringer Hepes; L-NAME, N G -nitro-L-arginine methyl ester; MMTS, methylmethane thiosulfonate; 7NI, 7-nitroindazole; NOS, NO synthase; nNOS, neuronal NOS; PSD, postsynaptic density; SNAP, S-nitroso-N-acetyl-DL-penicillamine; SNOC, S-nitrosocysteine; TNE, Tris/Nonidet P40/EDTA; TRH, thyrotrophin (TSH)-releasing hormone. 1 To whom correspondence should be addressed at the present address: Department of Pharmacology, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan (email yasuwata@ac.shoyaku.ac.jp).
rat CaM was expressed in Escherichia coli BL21 (DE3) cells using the pET-CM vector, kindly provided by Dr Nobuhiro Hayashi (Division of Biomedical Polymer Science, Fujita Health University, Toyoake, Japan) [25] . NG108-15 neuroblastoma × glioma hybrid cells were a gift from Dr Haruhiro Higashida (Department of Biophysical Genetics, Kanazawa University Graduate School of Medicine, Kanazawa, Japan) [26] . The rabbit polyclonal antibody, NP847, recognizing phosphorylation at Ser 847 on nNOS, was prepared as described previously [6] . The rabbit polyclonal anti-CaMKIIδ antibody was prepared as described previously [27] . The mouse monoclonal anti-CaMKIIα antibody was from BD Biosciences and the rabbit polyclonal anti-(active-CaMKII) antibody, recognizing phosphorylation at Thr 286 on CaMKII, was from Promega. A23187, L-NAME (N Gnitro-L-arginine methyl ester), TRH [thyrotrophin (TSH)-releasing hormone] and calmizazolium were obtained from Sigma, and 7NI (7-nitroindazole) was bought from Calbiochem. SNAP (S-nitroso-N-acetyl-DL-penicillamine) was from Dojindo Laboratory (Kumamoto, Japan) and DEA-NONOate (diethylamineNONOate) from Alexis. [γ -
32 P]ATP (6000 Ci/mmol) and ECL (enhanced chemiluminescence) immunoblotting detection reagents were from GE Healthcare, and restriction enzymes and DNA modifying enzymes were obtained from TaKaRa (Osaka, Japan). Electrophoresis reagents were from Bio-Rad. All other materials and reagents were of the highest quality available from commercial suppliers. Wistar rats (male, 10 weeks old, 270-300 g; Nihon SLC, Hamamatsu, Japan) were used for pharmacological treatment of tissue slices. All animals were maintained and handled in accordance with the guidelines of the Declaration of Helsinki and the Guiding Principles in the Care and Use of Animals of the Showa Pharmaceutical University.
Plasmid construction
The plasmid pME18s-nNOS was generated as described previously [22] . The CaMKIIα mutants C6A, C30A, C64A, C115A, C126A, C199A, C280A, C289A, C373A, C428A and C6A/C30A (i.e., a mutant bearing replacements of both Cys 6 and Cys 30 with alanine residues) were each subcloned into pME18s. The nucleotide sequences of each mutant were confirmed by DNA sequencing. 
Preparation of lysates and immunoprecipitation
For preparation of lysates, cells were homogenized by sonication with TNE (Tris/Nonidet P40/EDTA) buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 10 μg/ml leupeptin, 1 μg/ml pepstatin A, 1 μg/ml aprotinin, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 2 mM sodium pyrophosphate and 1 % Nonidet P40]. After centrifugation at 15 000 g for 15 min at 4
• C, the supernatant was boiled with SDS/PAGE sample buffer, and then analysed by SDS/PAGE (7.5 % gels) followed by Western-blot analysis using NP847 (1:500 dilution; Santa Crux Biotechnology) antibody, anti-nNOS antibody (1:1000 dilution; Santa Cruz Biotechnology), rabbit polyclonal anti-(active-CaMKII) antibody (1:1000 dilution), mouse monoclonal anti-CaMKIIα antibody (1:2500 dilution) and rabbit polyclonal anti-CaMKIIδ antibody (1:1000 dilution). Immunoprecipitation of CaMKII from GH3 cells was performed essentially in the dark. Lysates were pre-cleared by centrifugation with an excess amount of Protein G-Sepharose (GE Healthcare), and then incubated with 1 μg of purified pre-immune rabbit IgG or CaMKIIδ antibody for 1 h at 4
• C. Immune complexes were collected on 30 μl of Protein G-Sepharose [50 % (v/v) slurry] and washed once with 400 μl of TNE buffer and twice with 400 μl of TNE buffer without Nonidet P40. The beads were used for an in vitro kinase assay using syntide2 (PLARTLSVAGLPCKK) as the substrate.
Kinase assays
Purified CaMKIIα (200 nM) and nNOS (2 μM) were preincubated in a buffer containing 40 mM Tris/HCl (pH 7.5), 2 mM CaCl 2 , 5 μM CaM, 20 μM BH4, 100 μM NADPH, 4 μM FAD, and 4 μM FMN (control) and L-NAME (1 mM) in the presence or absence of 3 mM L-arginine for 40 min at 25
• C. Purified CaMKIIα (200 nM) was also pre-incubated with NO donor compounds for 40 min at 25
• C in a buffer containing 250 mM Hepes/NaOH (pH 7.7) and 0.5 mM EDTA. Then CaMKII activity was measured at 30
• C for 2 min in 40 mM Hepes/NaOH (pH 7.0), 10 mM MgCl 2 , 1 mM CaCl 2 , 1 μM CaM, 250 nCi of [γ -32 P]ATP, 100 μg/ml BSA, 50 μM syntide2 and 50 nM recombinant CaMKIIα or immune complex from cell lysates in a final volume of 25 μl (total activity). In some experiments, CaMKII activity was also assayed using 1 mM EGTA (Ca 2+ -independent activity) instead of 1 mM CaCl 2 and 1 μM CaM. 32 P incorporation was determined by spotting 20 μl aliquots of the assay mixture on to Whatman P-81 phosphocellulose paper, followed by washing in 75 mM phosphoric acid [28] .
Autophosphorylation of CaMKII
Autophosphorylation of CaMKII (1.2 μM) was carried out using the purified enzyme in 40 mM Hepes/NaOH (pH 7.0), 5 mM MgCl 2 , 1 mM CaCl 2 , 10 μM CaM, 500 μM ATP and 500 μg/ml BSA for 10 min on ice. Then Ca 2+ /CaM-independent autophosphorylation was performed by the addition of 2 mM EGTA to the mixture. The reactions were terminated after a further 10 min incubation on ice by the addition of EDTA (10 mM final concentration).
Purification of expressed proteins
Recombinant rat nNOS proteins were expressed in E. coli and purified by 2 -5 -ADP-agarose (Sigma) as described previously [29] . Recombinant rat CaMKIIα proteins were expressed in Sf9 cells and purified by CaM-Sepharose chromatography as described previously [6] . Protein concentrations were determined by the method of Bradford using BSA as the protein standard [29a] .
Biotin switch assay
S-nitrosylated proteins were detected using a biotin switch assay, performed essentially in the dark as described previously [21] . Cells were homogenized in HEN (Hepes, EDTA and neocuprione) buffer [250 mM Hepes/NaOH (pH 7.7), 1 mM EDTA and 0.1 mM neocuprione] with 150 mM NaCl, 1 % Nonidet P40 and 20 mM MMTS (methylmethane thiosulfonate) and the homogenate was incubated at 4
• C for 30 min. The lysate was cleared by centrifugation at 10 000 g for 15 min at 4
• C. SDS [2.5 % (w/v)] was then added and the supernatant was incubated at 50
• C for 30 min with frequent vortexing. The MMTS was then removed by adding 2 volumes of 100 % acetone and the proteins were precipitated at − 20
• C for 20 min. After removal of the acetone, the proteins were resuspended in HEN buffer containing 1 % (w/v) SDS. Freshly prepared N- [6-(biotinamido) hexyl]-3 -(2 -pyridyldithio)propionamide (2.2 mg/ml in dimethylformamide) and sodium ascorbate were added to a final concentration of 0.2 mM and 8 mM respectively. After incubation for 1 h at 25
• C, biotinylated proteins were precipitated by streptavidin-agarose beads. The streptavidin-agarose was then pelleted (2000 g for 10 min at 4
• C) and washed five times [20 mM Hepes/NaOH (pH 7.7), 1 mM EDTA, 100 mM NaCl and 0.5 % Triton X-100]. The biotinylated proteins were eluted with an elution buffer [20 mM Hepes/NaOH (pH 7.7), 1 mM EDTA, 100 mM NaCl and 100 mM 2-mercaptoethanol] and subjected to Western-blot analysis.
Pharmacological treatment of tissue slices
Pharmacological stimulation in rat hippocampal slices was performed as described previously [30] . Briefly, rat brains were quickly removed and kept in ACSF (artificial cerebrospinal fluid) (128 mM NaCl, 1.7 mM KCl, 26 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 2.4 mM CaCl 2 , 1.3 mM MgSO 4 and 10 mM glucose) continuously saturated with a mixture of 95 % O 2 /5 % CO 2 . The hippocampi were dissected out and sliced in two directions at a thickness of 500 mm using a McIlwain tissue chopper (Mickle Laboratory Engineering, Gomshall, Guildford, Surrey, U.K.) before incubation at 37
• C for 1 h in a netwell chamber (Corning) filled with ACSF, and then exposed to glutamate (1 mM or 5 mM), 7NI (100 μM) or SNOC (S-nitrosocysteine, 100 μM) for the indicated times. After a wash in ice-cold ACSF, the slices were homogenized in modified HEN buffer for examination by the biotin switch method.
Statistical analysis
All results are expressed as the means + − S.E.M. Statistical differences among values for individual groups were determined by ANOVA, followed by the Student-Newmann-Keuls multiple comparisons test when F ratios were considered to be significant (P < 0.05).
RESULTS
Inhibiting nNOS enhanced TRH-induced nNOS phosphorylation at Ser 847 in GH3 cells
It is known that GH3 cells express nNOS and CaM-dependent protein kinases and that TRH activates their CaMKs [31] . CaMKII can phosphorylate nNOS at Ser 847 in cells [22] . In initial experiments, we determined the effects of TRH on phosphorylation of Ser 847 in GH3 cells using an anti-phosphopeptide antiserum, NP847, specific to the Ser 847 -PO 4 nNOS form [6] . When GH3 cells in KRH solution (containing 2.7 mM Ca 2+ ) were treated with TRH, phosphorylation of Ser 847 was observed, Lysates were prepared, and total nNOS and phosphorylation of nNOS at Ser 847 were monitored as described in (A). Expressed CaMKII and autophosphorylated CaMKII (p-Thr 286 ) were also analysed by Western blotting using the rabbit polyclonal anti-CaMKIIδ antibody and the rabbit polyclonal anti-(active-CaMKII) antibody respectively. The histograms show amounts of phosphorylated Ser 847 nNOS relative to that of nNOS (left panel) and immunoreactive phosphorylated Thr 286 CaMKII relative to that of CaMKII (right panel) in the presence (+ 7NI) or absence (− 7NI) of 7NI in the membrane at each time point (n = 3). * , P < 0.05; * * , P < 0.01; * * * , P < 0.001. A. U., arbitrary units. (C) GH3 cells were treated with buffer alone or with TRH (1 μM) for 10 min either in the presence of or absence of 7NI (100 μM) as indicated. Lysates were immunoprecipitated with either pre-immune rabbit IgG or an antibody against CaMKIIδ. Each immune complex was used for an in vitro kinase assay using 50 μM syntide2 as the substrate. The kinase activity was expressed (CaM-KII activity) following subtraction of the levels in the immune complex with pre-immune rabbit IgG (n = 6). * * , P < 0.01; * * * , P < 0.001.
with maximum stimulation at 10 min ( Figures 1A and 1B) . The removal of extracellular Ca 2+ almost completely blocked this phosphorylation ( Figure 1A) . Treatment of GH3 cells either with calmidazolium (a CaM antagonist) or KN-93 (an inhibitor of CaMKs), significantly blocked TRH-induced phosphorylation of Ser 847 ( Figure 1A ). Addition of 7NI (an inhibitor of NOS), increased the phoshorylation ( Figure 1B ). Next we examined whether CaMKII activity could be regulated directly by nNOS activation in GH3 cells, using two methods. First, it is well established that CaMKII can undergo rapid autophosphorylation at Thr 286 , which appears to precede the phosphorylation of substrates [32] . We therefore examined the levels of autophosphorylated CaMKII at Thr 286 in GH3 cells using an active CaMKII antibody specific for Thr 286 -phosphorylated CaMKII. Protein immunoblot analyses of treated GH3 extract detected an immunoreactive band corresponding to CaMKII, which immediately increased after TRH treatment and was sustained thereafter ( Figure 1B ). In addition, the immunoreactive signals were significantly enhanced when cells were pre-treated with 7NI ( Figure 1B) . Second, we employed the CaMKII immunoprecipitation/kinase assay technique. After pre-treatment of cells with 7NI, basal and TRH-stimulated CaMKII activities were increased significantly ( Figure 1C ). The stimulation of cells with TRH alone significantly enhances CaMKII activity.
NO reversibly inactivates CaMKII in vitro
nNOS has been shown to generate NO in the presence, but not in the absence, of L-arginine [33] . To assess whether NO from isolated nNOS may be involved in the regulation of CaMKII activity, an in vitro kinase assay was employed. Purified CaMKII was incubated with nNOS either in the presence or absence of L-arginine and then assayed for enzyme activity. A decrease in activity to approx. 60 % was evident in the presence of Larginine (Figure 2A ). This was not the case with heat-inactivated nNOS maintained at 60
• C for 10 min (results not shown). Once inhibited by incubation with nNOS plus L-arginine, CaMKII was observed to re-activate rapidly on addition of 20 mM DTT (dithiothreitol), an SH-reducing agent ( Figure 2B ). To explore the effects of exogenous NO on CaMKII activity, we pretreated the enzyme with increasing amounts of various NO donors, including DEA-NONOate or SNAP. With both reagents, CaMKII activity was inhibited in a dose-dependent manner ( Figure 3A) ; this was again reversed by the addition of 20 mM DTT ( Figure 3B ). To examine further the effect of Ca 2+ /CaM on NO-induced inactivation of CaMKII, we pre-treated the enzyme with DEA-NONOate either in the presence or the absence of Ca 2+ /CaM. Pre-treatment of purified CaMKII with Ca 2+ /CaM itself caused a decrease in the enzyme activity to approx. 70 % compared with the untreated kinase ( Figure 3C ). CaMKII activity was inhibited by DEA-NONOate (0.3 mM) to approx. 60 % or 80 % in the presence or absence of Ca 2+ /CaM respectively ( Figure 3C ). It is well established that autophosphorylation of CaMKII can generate a largely Ca 2+ -independent enzyme. Autophosphorylation of CaMKII under the conditions employed resulted in up to 50% Ca 2+ -independent activity being observed ( Figure 3D ). Autophosphorylated CaMKII activity was inhibited by DEA-NONOate (0.3 mM) to approx. 40 % and 24 % activity in the presence or absence of 1 mM CaCl 2 /1 μM CaM (total activity) and 1 mM EGTA (Ca 2+ -independent activity) respectively ( Figure 3D ).
Cys 6 is an essential site for inactivation of CaMKII
Rat brain CaMKIIα contains ten cysteine residues ( Figure 4A ). To determine which cysteine residue(s) are sensitive to NO donorinduced inactivation, we generated mutants of rat CaMKIIα in which each of the ten cysteine residues were replaced by alanine residues. We first defined the direct effect of cysteine to alanine mutations on the enzyme activity in HEK-293 cells, which contain undetectable CaMKII levels, as determined by immunoblotting ( Figure 4B ). The enzyme activities of wild-type and single cysteine to alanine mutants in the cell lysates were similar ( Figure 4B ). Wild-type and single cysteine to alanine mutants were also expressed in NG108-15 cells and an in vitro kinase assay was employed using cell lysates. Treatment of solubilized lysates from cells expressing the wild-type enzyme with DEA-NONOate (1 mM) resulted in an inhibition of enzyme activity. CaMKIIα mutants C6A and C30A appeared to be partially resistant to DEANONOate-induced inactivation. The other CaMKIIα mutants (C64A, C115A, C126A, C199A, C280A, C289A, C373A and C428A) demonstrated no remarkable effects ( Figure 4C) . Next, the wild-type and C6A, C30A and C6A/C30A CaMKIIα mutants were expressed and purified using the baculovirus/Sf9 cell system. All the recombinant CaMKIIs were at least 90 % pure and resolved as a major band at 50 kDa on SDS/PAGE with Coomassie Brilliant Blue staining ( Figure 5A ). With increasing amounts of DEA-NONOate no decrease in activity was noted 
(arbitrary units). (D) Effects of NO on Ca
2+ -independent activity of CaMKIIα. Autophosphorylated CaMKIIα (400 nM) was pre-incubated in a buffer containing 250 mM Hepes (pH 7.7), 0.5 mM EDTA and 400 μg/ml BSA with buffer alone (−) or DEA-NONOate (+, 0.3 mM) for 40 min at 25 • C. Equivalent amounts (50 nM) of CaMKIIα were assayed for 3 min using 50 μM syntide2 and either 1 mM CaCl 2 /1 μM CaM (Total activity) or 1 mM EGTA (Ca 2+ -independent activity) (n = 3). * * * , P < 0.001. A. U., arbitrary units.
with C6A and C6A/C30A CaMKIIα mutants, whereas wild-type CaMKII was significantly inactivated ( Figure 5B) . Notably, the C30A CaMKIIα mutant displayed a 10-fold reduction in sensitivity to inhibition by DEA-NONOate relative to the wildtype enzyme. Recombinant CaMKIIs were also incubated with nNOS either in the presence or absence of L-arginine and then assayed for CaMKII activity. The enzyme activity was decreased to 60-70 % when wild-type CaMKII or C30A was incubated in the presence of L-arginine ( Figure 5C ). However, the C6A and C6A/C30A CaMKIIα mutants proved to be resistant to a decrease in enzyme activity. We next tested whether modification of Cys 6 is sufficient to dampen CaMKII activity in cells. We co-expressed nNOS either with wildtype CaMKIIα or the C6A mutant in HEK-293 cells and monitored phosphorylation of Ser 847 of nNOS or autophosphorylation of CaMKII at Thr 286 on stimulation with the calcium ionophore A23187. In the absence of stimulation, cells expressing wild-type CaMKIIα or the C6A mutant showed faint or undetectable phosphorylation of Ser 847 of nNOS or autophosphorylation of CaMKII at Thr 286 . A23187 treatment led to an increase in phospho-nNOS/CaMKII in both cells, but especially in cells expressing C6A CaMKIIα (see Supplementary Figure 1 at http://www.BiochemJ.org/bj/412/bj4120223add.htm). The A23187-induced increase in the phospho-nNOS/CaMKII in cells expressing wild-type CaMKIIα was enhanced by 7NI, but this was not the case for C6A CaMKIIα.
Cys 6 is the site of S-nitrosylation on CaMKII
We next determined whether S-nitrosylation of CaMKIIα at Cys 6 could mediate NO inhibition of the enzyme. N293 cells, HEK-293 cells stably expressing nNOS [34] , were transfected with wild-type CaMKIIα or C6A and examined for S-nitrosylation of CaMKIIs using the biotin switch assay. When cells are saturated with L-arginine, in situ treatment of A23187 is known to stimulate nNOS catalytic activity [35] . The S-nitrosylation of wild-type CaMKIIα was enhanced by A23187 treatment; however, S-nitrosylation of CaMKIIα C6A was not affected by the treatment (see Supplementary Figure 2A at http://www.BiochemJ. org/bj/412/bj4120223add.htm). To determine whether Cys 6 is accessible to S-nitrosylation by an exogenous NO donor, we employed a MS-based method that can identify S-nitrosylated peptides in digests of DEA-NONOate-treated proteins. Following exposure of purified CaMKIIα to DEA-NONOate, V8 protease digestion was performed and peptides were introduced by ESI (electrospray ionization) into a hybrid quadrupole time-of-flight MS. ESI-MS was performed as stated in the Supplementary Figure 2B ). Notably, prior to DEA-NONOate treatment, peptides were undetectable. Recombinant CaMKIIα from Sf9 cells was produced with N-terminal acetylation. Modification of the V8 protease-digested peptide containing Cys 6 is summarized in Table 1 .
S-nitrosylation of CaMKII in the hippocampus
We next determined whether S-nitrosylation of CaMKII could occur in brain after nNOS activation. In rat hippocampal slices, endogenous CaMKII was S-nitrosylated by glutamate stimulation, and this reaction was inhibited by 7NI ( Figure 6 ). SNOC also markedly enhanced the level of S-nitrosylated CaMKII in the hippocampus.
DISCUSSION
The present paper documents evidence that NO is a potent inhibitor of CaMKII through S-nitrosylation of Cys 6 of CaMKII.
Since exogenous NO donors do not always accurately reflect the NO released from nNOS-expressing cells [33] , activation by TRH or a calcium ionophore in cells expressing nNOS and CaMKII was selected here as an appropriate model for examining NO signalling involved in the regulation of CaMKII. CaMKII is thought to catalyse nNOS phosphorylation at Ser 847 directly via TRH stimulation in GH3 cells because this phosphorylation is sensitive to extracellular Ca 2+ , the CaM antagonist calmidazolium and the CaMK inhibitor KN-93 (Figures 1 and 2) . CaMKII phosphorylates nNOS at Ser 847 in cells, but CaMKI and CaMKIV do not [23, 36] . Kinetic studies revealed the specific activity of C6A CaMKIIα to be indistinguishable from that of the wild-type enzyme (results not shown), confirming that Cys 6 itself does not contribute to CaMKII catalysis. Cys 30 is located on the ATPbinding site and the C30A CaMKIIα mutant displayed a 10-fold reduction in sensitivity to inhibition by DEA-NONOate relative to the wild-type enzyme ( Figure 5B ). However, like the wildtype enzyme, the CaMKIIα C30A mutant was inactivated by NO derived from nNOS ( Figure 5C ). Both nNOS and CaMKII require the same activator, Ca 2+ /CaM. CaMKII is known to be regulated by autophosphorylation, which increases its Ca 2+ -independent activity. Because CaM-CaMKII binding is not essential for inactivation of the enzyme by NO in vitro ( Figure 3C ), Ca 2+ -independent CaMKII would also be sensitive to NO-induced • C, and enzyme activity was measured as described in Figure 3 . (C) Cys 6 mediating inhibition of CaMKIIα activity by NO derived from isolated nNOS. Purified wild-type (WT) and mutated CaMKIIα [C6A (6CA), C30A (30CA) and C6A/C30A (6,30CA)] forms were incubated with nNOS either in the presence of (+) or absence of (−) 3 mM L-arginine for 40 min at 25 • C. Equivalent amounts (50 nM) of CaMKIIα were used for the enzyme activity assay as described in Figure 2 (n = 3) .
inactivation, consistent with the results shown in Figure 3(D) . The S-Nitrosylation of CaMKII on Cys 6 occurs by NO derived from nNOS (Supplementary Figure 1) as well as by exogenous NO (Supplementary Figure 2) . S-nitrosylated peptides other than ATITCTRFTEE could not be detected by MS. Although the results of the present study do not exclude the potential involvement of other S-nitrosylation sites targeted by NO, only Cys 6 S-nitrosylation appears to be necessary for the inactivation of CaMKII by NO. Activated glial and inflammatory cells are characterized Table 1 Modification of the V8 protease-digested peptide which contains Cys 6 The CaMKIIα V8-protease-digested peptide sequence is MATITCTRFTEE, with the modified methionine and cysteine residues indicated in bold and underlined. by the presence of inducible NOS, which produces a Ca 2+ -independent NOS. S-Nitrosylation of CaMKII could also occur via NO released by these cells. Indeed, treatment of rat hippocampal slices with a Ca 2+ -independent NOS, SNOC (100 μM), increased the level of S-nitrosylation of CaMKII ( Figure 6 ). S-nitrosylation of CaMKII is thought to be physiological, since it occurs after nNOS activation in the hippocampus ( Figure 6 ). However, its actual physiological and pathological significance remains to be determined as, from the primary structure of rat CaMKIIα, Cys 6 is located in neither the ATP binding domain nor the catalytic domain ( Figure 4A ). Caenorhabditis elegans contains CaMKII, in which Cys 6 is not conserved [37] , and does not encode NOS [38] , suggesting that C. elegans CaMKII is not able to respond to NO. Thus the molecular mechanisms whereby NO regulates CaMKII activity will need to be elucidated.
What are the downstream physiological events controlled by NO-induced S-nitrosylation of CaMKII at Cys 6 ? Endogenous NO is known to inhibit secretion of growth hormone in GH3 cells [39] . CaMK regulates the secretion of gonadotropinreleasing hormone in pituitary cells [40] . GH3 cells express CaMKIIδ. Alignment of CaMKII sequences from four isoforms (α, β, γ and δ) revealed that Cys 6 is conserved [41] . Thus NO-induced inactivation of CaMKII via Cys 6 S-nitrosylation might be involved in the mechanism of controlling hormone secretion in GH3 cells. Blockade of NO synthesis with 7NI in GH3 cells would be expected to potentiate CaMKII activity, leading to phosphorylation of nNOS at Ser 847 ( Figures 1B and  1C) . CaMKII has been implicated in the phosphorylation of nNOS at Ser 847 , leading to a reduction in its enzyme activity [22, [42] [43] [44] . Meanwhile TRH stimulates NO release from GH3 cells [45] , thereby reducing CaMKII enzyme activity. However, CaMKII activity was enhanced by in situ treatment of TRH ( Figure 1C) . It is possible that CaMKII activity is already inhibited by basal release of NO, and TRH inhibits nNOS activity via phosphorylation of Ser 847 in the conditions employed. Studies of nNOS Ser 847 phosphorylation in the nervous system have indicated that down-regulation of nNOS activity by CaMKII may represent an important component of the cross-talk between Ca 2+ -and NO-regulated signal transduction pathways [22, 42, 46] . Brain ischaemia causes overproduction of NO, allowing its conversion into peroxynitrite, which can cause neuronal cell death [47] . Forebrain ischaemia induces loss of CaMKII activity [48] . Thus Cys 6 S-nitrosylation of CaMKII might be involved in ischaemiainduced post-translational modifications [49] .
In conclusion, we have in the present paper demonstrated for the first time that NO released from nNOS, as well as exogenous NO, is a reversible, redox-mediated regulator of CaMKII via Snitrosylation of Cys 6 of CaMKII. On the basis of the model shown in Figure 7 , we propose that phosphorylation and NO signalling are mutually regulated through phosphorylation of nNOS at Ser 847 and S-nitrosylation of CaMKII at Cys 6 respectively. It is known that CaMKII activity plays some neuroprotective role in the ischaemic brain [50] and that nNOS/CaMKII co-localizes in the rat hippocampus even after transient forebrain ischaemia [46] . NO-induced inactivation of CaMKII is thus a possible source of neurotoxicity, and could become a target for therapy. Clearly the influence of S-nitrosylation and its control areas warrant further elucidation.
